[go: up one dir, main page]

AR023099A1 - Constructos de adn que codifican saratina y sus usos. - Google Patents

Constructos de adn que codifican saratina y sus usos.

Info

Publication number
AR023099A1
AR023099A1 ARP000101192A ARP000101192A AR023099A1 AR 023099 A1 AR023099 A1 AR 023099A1 AR P000101192 A ARP000101192 A AR P000101192A AR P000101192 A ARP000101192 A AR P000101192A AR 023099 A1 AR023099 A1 AR 023099A1
Authority
AR
Argentina
Prior art keywords
collagen
natural
protein
cells
saratina
Prior art date
Application number
ARP000101192A
Other languages
English (en)
Inventor
Wolfgang Strittmatter
Detlef Guessow
Uwe Hofmann
Juergen Hemberger
Zisi Fotev
Bernhard Scheuble
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR023099A1 publication Critical patent/AR023099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una proteína natural aislada de la saliva de la sanguijuela medicinal Hirudo medicinalis que se une fuertemente al colágeno, actuando de estamanera como un inhibidor de la adherencia natural de las plaquetas al colágeno. La proteína tieneun peso molecular de aproximadamente 12000, un puntoisoeléctrico ácido y contiene seis cisteínas. La proteína fue secuenciada y el gen fue clonado a partir de la biblioteca de ADNc de H. Medicinalis. También sedan a conocer procedimientos para producir tal polipéptido por medio de técnicas recombinantes. Tanto las proteínas naturales como las quiméricas soninhibidores potentes de la adherencia de plaquetas dependiente del colágeno y, por lo tanto, pueden ser utilizadas para el tratamiento terapéutico de diversascondiciones relacionadas con la enfermedad cardíaca y las enfermedades del sistema circulatorio. Además, la proteína también es apropiada para recubrirsuperficies naturales o artificiales de colágeno con el fin de volverlas no adhesivas para las células y de esta manera prevenir la activacion de células.
ARP000101192A 1999-03-18 2000-03-17 Constructos de adn que codifican saratina y sus usos. AR023099A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99105530 1999-03-18
EP99109503 1999-05-12

Publications (1)

Publication Number Publication Date
AR023099A1 true AR023099A1 (es) 2002-09-04

Family

ID=26152935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101192A AR023099A1 (es) 1999-03-18 2000-03-17 Constructos de adn que codifican saratina y sus usos.

Country Status (27)

Country Link
US (3) US6774107B1 (es)
EP (1) EP1161530B1 (es)
JP (1) JP4805461B2 (es)
KR (1) KR100788219B1 (es)
CN (1) CN1185344C (es)
AR (1) AR023099A1 (es)
AT (1) ATE295883T1 (es)
AU (1) AU767172B2 (es)
BR (1) BR0009074A (es)
CA (1) CA2367457C (es)
CO (1) CO5241328A1 (es)
CZ (1) CZ301524B6 (es)
DE (1) DE60020220T2 (es)
DK (1) DK1161530T3 (es)
ES (1) ES2240067T3 (es)
HK (1) HK1045330B (es)
HU (1) HU228068B1 (es)
MX (1) MXPA01009363A (es)
MY (1) MY123371A (es)
NO (1) NO330769B1 (es)
PL (1) PL200384B1 (es)
PT (1) PT1161530E (es)
RU (1) RU2292351C2 (es)
SI (1) SI1161530T1 (es)
SK (1) SK287496B6 (es)
TR (1) TR200102729T2 (es)
WO (1) WO2000056885A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020220T2 (de) * 1999-03-18 2006-05-24 Merck Patent Gmbh Plättchenadhäsion blockierendes protein
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
AU2002333241B2 (en) * 2001-07-18 2008-09-18 Merck Patent Gmbh Glycoprotein VI fusion proteins
US7053051B2 (en) 2003-10-28 2006-05-30 Medtronic, Inc. Methods of preparing crosslinked materials and bioprosthetic devices
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP5762666B2 (ja) * 2004-10-12 2015-08-12 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティＢｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｍｉｃｈｉｇａｎ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ フロログルシノールの生合成およびそれからの１，３−ジヒドロキシベンゼンの製造
WO2006128152A2 (en) * 2005-05-26 2006-11-30 Thomas Jefferson University Method to treat and prevent posterior capsule opacification
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20080015145A1 (en) 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
CN109797150A (zh) 2008-10-15 2019-05-24 Ionis制药公司 因子11表达的调节
WO2012003461A2 (en) 2010-07-02 2012-01-05 Draths Corporation Phloroglucinol synthases and methods of making and using the same
WO2012006244A1 (en) 2010-07-06 2012-01-12 Draths Corporation Method for producing phloroglucinol and dihydrophloroglucinol
WO2012006245A1 (en) 2010-07-06 2012-01-12 Draths Corporation Phloroglucinol reductase and methods of making and using the same
PT3333188T (pt) 2010-08-19 2022-03-28 Zoetis Belgium S A Anticorpos de anti-ngf e a sua utilização
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
AU2013292617A1 (en) 2012-07-19 2015-01-22 Zoetis Llc Bovine influenza C virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
WO2018035199A1 (en) 2016-08-17 2018-02-22 Pharmaq As Sea lice vaccine
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
KR102828306B1 (ko) 2018-03-16 2025-07-01 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
KR102672548B1 (ko) 2018-03-16 2024-06-04 조에티스 서비시즈 엘엘씨 인터루킨-31에 대한 펩티드 백신
PE20210393A1 (es) 2018-05-09 2021-03-02 Ionis Pharmaceuticals Inc Compuestos y metodos para la reduccion de la expresion de fxi
BR112022004488A2 (pt) 2019-09-11 2022-05-31 Zoetis Services Llc Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
US12440556B2 (en) 2020-06-15 2025-10-14 Zoetis Services Llc Genetically modified cell line for production of Marek's disease virus vaccine and methods of making and using the same
JP2023544839A (ja) 2020-10-07 2023-10-25 ゾエティス・サービシーズ・エルエルシー 抗ｎｇｆ抗体及びその使用方法
US12180290B2 (en) 2020-10-19 2024-12-31 Zoetis Services Llc Antibodies to canine and feline oncostatin M receptor beta and uses thereof
CA3232382A1 (en) 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705355A (en) * 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
US4898734A (en) 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
US5182260A (en) * 1989-01-27 1993-01-26 Biogen, Inc. Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
CA2052486A1 (en) * 1990-10-09 1992-04-10 Thomas M. Connolly Protein for inhibiting collagen-stimulated platelet aggregation
GB9022040D0 (en) * 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
DE4136513A1 (de) * 1991-11-06 1993-05-13 Basf Ag Neues thrombininhibitorisches protein aus raubwanzen
ATE210679T1 (de) * 1993-07-01 2001-12-15 Merck Patent Gmbh Ein inhibitor der collagenstimulierten plättchenaggregation
PT711158E (pt) 1993-07-29 2004-04-30 Us Gov Health & Human Serv Metodo para tratar aterosclerose ou restenose utilizando um agente de estabilizacao dos microtubulos
CA2199719A1 (en) * 1994-09-12 1996-03-21 Christiane Noeske-Jungblut Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
JP4278175B2 (ja) * 1994-10-28 2009-06-10 ヴァイタリーチ バイオサイエンス エン．フェー． プロテアーゼ阻害剤および他の生物活性物質の新しい系
DE60020220T2 (de) 1999-03-18 2006-05-24 Merck Patent Gmbh Plättchenadhäsion blockierendes protein
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen

Also Published As

Publication number Publication date
HUP0200353A2 (hu) 2002-05-29
NO20014506L (no) 2001-11-16
CA2367457A1 (en) 2000-09-28
MXPA01009363A (es) 2002-06-04
EP1161530B1 (en) 2005-05-18
JP2002539788A (ja) 2002-11-26
NO20014506D0 (no) 2001-09-17
US7090986B2 (en) 2006-08-15
US20050065084A1 (en) 2005-03-24
EP1161530A1 (en) 2001-12-12
DE60020220T2 (de) 2006-05-24
MY123371A (en) 2006-05-31
US6962801B2 (en) 2005-11-08
CA2367457C (en) 2010-09-21
CZ20013341A3 (cs) 2002-01-16
KR100788219B1 (ko) 2007-12-26
PT1161530E (pt) 2005-09-30
SK12902001A3 (sk) 2002-03-05
DE60020220D1 (de) 2005-06-23
NO330769B1 (no) 2011-07-11
ATE295883T1 (de) 2005-06-15
HK1045330B (zh) 2005-09-09
HK1045330A1 (en) 2002-11-22
PL200384B1 (pl) 2008-12-31
CO5241328A1 (es) 2003-01-31
TR200102729T2 (tr) 2002-04-22
DK1161530T3 (da) 2005-08-08
ES2240067T3 (es) 2005-10-16
RU2292351C2 (ru) 2007-01-27
CN1185344C (zh) 2005-01-19
BR0009074A (pt) 2002-01-02
AU3166200A (en) 2000-10-09
CZ301524B6 (cs) 2010-03-31
KR20020008131A (ko) 2002-01-29
US20060094079A1 (en) 2006-05-04
WO2000056885A1 (en) 2000-09-28
HUP0200353A3 (en) 2003-12-29
HU228068B1 (en) 2012-09-28
AU767172B2 (en) 2003-11-06
SK287496B6 (sk) 2010-12-07
US6774107B1 (en) 2004-08-10
SI1161530T1 (en) 2005-10-31
PL350147A1 (en) 2002-11-04
CN1344318A (zh) 2002-04-10
JP4805461B2 (ja) 2011-11-02

Similar Documents

Publication Publication Date Title
AR023099A1 (es) Constructos de adn que codifican saratina y sus usos.
CN101553243B (zh) 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体
C. Schröder et al. Stimulation of protein (collagen) synthesis in sponge cells by a cardiac myotrophin‐related molecule from Suberites domuncula
HUP9800075A2 (hu) Nukleinsav-konstrukciók proteázokkal aktíválható hatóanyagok expresszálására valamint előállításuk és alkalmazásuk
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
ES2009590A6 (es) Metodo de preparacion de proteina de cadena pesada del factor tisular humano.
ATE426024T1 (de) C-c chemokin rezeptor 3: ckr-3 oder eos-l2
EP0410540A1 (en) Fibrinogen receptor antagonists
DK0808367T3 (da) Vaskulære slimhindeaddressiner samt anvendelse deraf
JPS59156284A (ja) ヒト−レラキシンｈ２遺伝子
DE68914316T2 (de) Polypeptide aus Vipergift und deren Genexpression.
PT1078054E (pt) Mp52/gdf-5 monomérica com actividade morfogenética do osso e agente medicinal contendo a mesma para a prevenção e tratamento de doenças da cartilagem e do osso
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
JP4701355B2 (ja) プロトロンビン活性化タンパク質
ECSP003383A (es) Proteina para bloquear la adherencia plaquetaria
JPH0570364A (ja) 骨への破骨細胞付着を阻害する組成物及び方法
ATE452970T1 (de) N-desoxyribosyltransferase aus lactobacillus, entsprechende nukleinsäuren darauf und ihre verwendungen
CA2648649A1 (en) Antagonists against interaction of pf4 and rantes
CN100432102C (zh) 血小板增进蛋白及其应用
DE60231816D1 (de) Menschliche alpha2-delta4-calciumkanal-untereinheit codierende cdna
JP2805384B2 (ja) 機能性ポリペプチド
SA98190913A (ar) طريقة حث وتكوين الخلايا المنشئة لمكونات الدم
JPH02138197A (ja) 内皮細胞から誘導された組換え血小板由来成長因子ａ−鎖

Legal Events

Date Code Title Description
FG Grant, registration